Fig 5. Patients with 8p21 deletion respond poorly to bortezomib treatment.

Patients diagnosed with MM and receiving bortezomib based treatment at 1^st line were selected to this study (n = 88). (A) left panel is the non-HDT patients that received bortezomib (Vel: Velcade®, n = 33) as 1^st line treatment and right panel is the non-HDT patients that did not respond to 1^st line bortezomib treatment or relapsed and treated with Lenalidomide based regimen as a 2^nd line treatment (n = 16). B. Left panel displays patients received high dose treatment and bortezomib as 1^st line treatment (n = 55) and right panel is the response to Lenalidomide based treatment as 2^nd line for relapse patients (n = 18). Details of the treatments are shown in materials & methods section. Chi-square test was performed to analyze results.